Form 4: Oruka Therapeutics CEO Granted Equity and Options

Oruka Therapeutics, Inc. CEO Lawrence Otto Klein was granted 76,700 shares of common stock and options to purchase 306,700 shares.

Summary

• Lawrence Otto Klein, Chief Executive Officer and Director of Oruka Therapeutics, Inc. (ORKA), acquired 76,700 shares of common stock.
• These common shares were granted at a price of $0 and increased his direct beneficial ownership to 929,038 shares.
• The common stock grant vests as to 1/16 of the shares on each March 14, June 14, September 14, and December 14 (or the immediately preceding trading day if not a trading day).
• Mr. Klein also acquired options to purchase 306,700 shares of common stock with an exercise price of $34.39 per share.
• These options were granted at a price of $0 and increased his direct beneficial ownership of derivative securities to 306,700 options.
• The options vest as to 1/48 of the underlying shares monthly, commencing from January 1, 2026, and expire on January 22, 2036.
• All transactions occurred on January 23, 2026.

Sentiment

Score: 5

Explanation: The filing is a routine disclosure of executive equity compensation, which is a neutral event in itself. It does not contain information that would inherently suggest a positive or negative sentiment regarding the company's operational or financial performance.

Positives

• The grants of common stock and stock options align the Chief Executive Officer's interests with those of shareholders, incentivizing long-term performance and value creation.
• Equity compensation is a standard practice for executive remuneration, designed to attract and retain key talent.

Negatives

• The issuance of new shares and options could lead to potential dilution for existing shareholders, although this is a common aspect of executive compensation plans.

Risks

• The value of the granted common stock and options is subject to the market price fluctuations of Oruka Therapeutics, Inc.'s shares.
• The vesting of both the common stock and options is contingent upon continued employment and specific vesting schedules, meaning the full benefit is not immediately realized.

Future Outlook

The filing details future vesting schedules for the granted common stock and stock options, with common stock vesting quarterly and options vesting monthly from January 1, 2026, through their respective periods.

Industry Context

This Form 4 filing is a routine disclosure of executive compensation in the form of equity grants, a common practice across industries, including biotechnology, to incentivize leadership and align their financial interests with company performance.

Stakeholder Impact

• Shareholders: Potential for minor dilution from new share issuance, but also benefit from increased alignment of CEO's interests with long-term company performance.
• Employees (specifically the CEO): Direct impact on personal wealth and long-term incentive compensation.

Next Steps

• Continued vesting of 76,700 shares of common stock on a quarterly basis (March 14, June 14, September 14, December 14).
• Continued monthly vesting of options to purchase 306,700 shares of common stock, commencing from January 1, 2026.

Key Dates

Keywords

Oruka Therapeutics, ORKA, SEC Form 4, Insider Transaction, Stock Grant, Stock Option, Executive Compensation, Lawrence Klein, CEO, Equity Award